Quick Answer
Atara Biotherapeutics, Inc. reported Net Income of $32.69 million for fiscal year 2025.
Atara Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | $32.69M +138.3% |
-$85.40M +69.1% |
-$276.13M -20.9% |
-$228.30M +32.9% |
-$340.14M -10.9% |
-$306.62M -5.4% |
| Diluted EPS | $2.57 +122.5% |
-$11.41 +82.5% |
-$65.19 -2810.3% |
-$2.24 +38.3% |
-$3.63 +12.5% |
-$4.15 |
| Total Assets | $20.23M -81.5% |
$109.10M -34.1% |
$165.50M -56.0% |
$376.42M -19.6% |
$468.13M -20.4% |
$588.12M +71.5% |
| Cash and Equivalents | $8.48M -66.1% |
$25.03M -3.1% |
$25.84M -72.2% |
$92.94M -12.4% |
$106.08M -47.1% |
$200.40M +169.7% |
| Stockholders Equity | -$38.50M +60.4% |
-$97.28M -198.0% |
$99.23M -21.6% |
$126.64M -54.7% |
$279.61M -39.5% |
$462.34M +59.0% |
| R&D Expense | $37.45M -75.3% |
$151.48M -32.6% |
$224.78M -17.5% |
$272.53M -3.4% |
$282.00M +15.3% |
$244.65M +13.2% |
| Operating Income | $35.86M +143.0% |
-$83.44M +69.8% |
-$276.01M +1.6% |
-$280.51M +17.6% |
-$340.46M -10.2% |
-$309.05M -4.5% |
| Shares Outstanding | 7.32M +25.0% |
5.86M +37.6% |
4.26M -95.6% |
95.93M +4.6% |
91.67M +10.0% |
83.37M +46.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.30M | +80.4% | -280.3% |
| Diluted EPS | September 30, 2025 | -$0.32 | +89.1% | -268.4% |
| Total Assets | September 30, 2025 | $30.17M | -78.9% | -18.3% |
| Cash and Equivalents | September 30, 2025 | $5.74M | -87.6% | -66.0% |
| Stockholders Equity | September 30, 2025 | -$36.63M | +59.5% | -4.5% |
| R&D Expense | September 30, 2025 | $2.92M | -93.3% | -60.0% |
| Operating Income | September 30, 2025 | -$3.57M | +83.6% | -211.8% |
| Shares Outstanding | September 30, 2025 | 7.21M | +25.6% | +3.3% |
- Atara Biotherapeutics, Inc. reported Net Income of $32.69 million for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed an increase of +138.3% in Net Income compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported Diluted EPS of $2.57 per share for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed an increase of +122.5% in Diluted EPS compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported Total Assets of $20.23 million for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed a decrease of -81.5% in Total Assets compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported Cash and Equivalents of $8.48 million for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed a decrease of -66.1% in Cash and Equivalents compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported Stockholders Equity of -$38.50 million for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed an increase of +60.4% in Stockholders Equity compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported R&D Expense of $37.45 million for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed a decrease of -75.3% in R&D Expense compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported Operating Income of $35.86 million for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed an increase of +143.0% in Operating Income compared to the prior fiscal year.
- Atara Biotherapeutics, Inc. reported Shares Outstanding of 7.32 million shares for fiscal year 2025.
- Atara Biotherapeutics, Inc. showed an increase of +25.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: